Skip to content

A Phase 1 Study of AJ1-11095 in Adults with Myelofibrosis Failed by a JAK2 Inhibitor

Status
Not yet recruiting
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-522033-64-00
Enrollment
4
Registered
2026-02-09
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myelofibrosis

Interventions

None listed

Sponsors

Ajax Therapeutics Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 10, 2026